Researchers to reveal trial results for dual agonism in type 1 diabetes Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes
7 Walker, E., Lo, K., & Gopal, P
Of course, people are taking GLP-1s for weight loss
Our expert team will work closely with you to develop a customized treatment plan for your unique needs and goals
listen to the podcast on spotify - To view or add a comment, sign in How do you make a proven therapy truly accessible for the patients who need it most
This shift has the potential to reshape long-term chronic disease management, reducing future burdens from type 2 diabetes, cardiovascular disease, and musculoskeletal conditions